Pneumoccal polysacchride conjugate vaccine

Patent metadata

Field	Value
Publication number	US-9884113-B2
Application number	US-201514729408-A
Country	US
Kind code	B2
Filing date	Jun 3, 2015
Priority date	Dec 22, 2005
Publication date	Feb 6, 2018
Grant date	Feb 6, 2018

Abstract

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.

First claim

The invention claimed is:

1. A method of immunising a human host against disease caused by Streptococcus pneumoniae serotype 19A infection comprising the step of administering to the host an immunoprotective dose of a Streptococcus pneumoniae immunogenic composition comprising 10 or more capsular saccharides from different S. pneumoniae serotypes conjugated to 3 or more different carrier proteins, wherein the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT); serotype 18C capsular saccharide conjugated to tetanus toxoid (TT); and serotype 1, 4, 5, 6B, 7F, 9V, 14 and 23F capsular saccharide conjugated to protein D from Haemophilus influenzae but does not comprise capsular saccharide from serotype 19A.

2. The method of claim 1 wherein the serotype 19F capsular saccharide is the only saccharide in the immunogenic composition conjugated to diphtheria toxoid.

3. The method of claim 1 wherein the immunogenic composition comprises serotype 19F capsular saccharide directly conjugated to the carrier protein.

4. The method of claim 1 wherein the immunogenic composition comprises serotype 19F capsular saccharide conjugated to the carrier protein via a linker.

5. The method of claim 1 wherein the immunogenic composition comprises serotype 19F capsular saccharide conjugated to the carrier protein using 1-cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP) chemistry.

6. The method of claim 1 wherein the ratio of carrier protein to serotype 19F capsular saccharide in the immunogenic composition is between 5:1 and 1:5.

7. The method of claim 1 wherein the average size of the serotype 19F capsular saccharide in the immunogenic composition is between 100-750 kDa.

8. The method of claim 1 wherein the dose of the serotype 19F saccharide conjugate in the immunogenic composition is between 1 and 10 μg of saccharide.

9. The method of claim 1 wherein the immunogenic composition comprises 4 different carrier proteins.

10. The method of claim 1 wherein the 3 or more different carrier proteins in the immunogenic composition are selected from the group consisting of diphtheria toxoid (DT), DT CRM 197 (a DT mutant), tetanus toxoid (TT), Fragment C of TT, dPly, PhtA, PhtB, PhtD, PhtE, PhtDE, OmpC, PorB and Haemophilus influenzae Protein D.

11. The method of claim 1 wherein the immunogenic composition comprises capsular saccharide 18C conjugated to tetanus toxoid, wherein 18C is the only capsular saccharide in the composition conjugated to tetanus toxoid.

12. The method of claim 1 , wherein the average size of the serotype 18C capsular saccharide in the immunogenic compositions is between 50-550 kDa.

13. The method of claim 4 wherein the immunogenic composition comprises serotype 19F capsular saccharide conjugated to the linker using 1-cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP) chemistry.

Assignees

• Glaxosmithkline Biologicals Sa
• Glaxosmithkline Biologicals Sa

Inventors

• Biemans Ralph Leon
• Garcon Nathalie Marie Josephe
• Hermand Philippe Vincent
• Poolman Jan
• Van Mechelen Marcelle Paulette

Classifications

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P27/14

  Decongestants or antiallergics · CPC title